Postlicensure monitoring of human papillomavirus (HPV) vaccines is important to demonstrate the population-level impact on clinical outcomes, to provide data to inform policy and practice, and to measure progress of immunization programs [1] . Using a variety of data sources and approaches, studies from Australia, Europe, North America, and New Zealand have been largely consistent in showing significant declines in HPVrelated outcomes among young women, particularly in settings that have achieved high coverage with HPV vaccines [2] [3] [4] . Though evidence of the impact of HPV vaccines on cervical infections and genital warts is growing, less is known about trends in precancerous high-grade cervical lesions [2] . Cervical lesions are clinically important outcomes to monitor because they are most closely related to the development of cervical cancer and because they are diagnoses that incur substantial morbidity, psychological distress, and treatment costs [5, 6] .
In countries that have national or regional healthcare and disease registries (eg, Australia and Denmark), data linkage studies are able to examine rates of HPV-associated outcomes in relation to individual vaccination status to assess direct effectiveness of vaccines [7] [8] [9] [10] [11] . Unfortunately, registries for these types of studies are not widely available in many settings, including the United States. In such areas, evidence of vaccine impact may be assessed by examining population-level trends in HPV-associated outcomes over time. A strength of this approach is that these trends reflect both direct and indirect effects of vaccination [12] . However, a challenge with this type of trend analysis is that declines due to the vaccine may not be easily disentangled from declines that might occur for other reasons. For example, in the United States, recent changes to cervical cancer screening guidelines that now recommend less frequent screening may also contribute to fewer diagnoses of cervical lesions [13] . First put forth in 2009 and more widely adopted in 2012, guidelines changed to recommend no screening prior to age 21 years and to lengthen the screening interval to every 3 years (instead of annually). Furthermore, because HPV is a sexually transmitted infection, declines may also be due to underlying changes in sexual behaviors.
We conducted the present analyses to describe trends in cervical lesions in Connecticut (CT) during 2008-2015 by single year of age and birth cohort. In CT, as in the rest of the United States, HPV vaccination was introduced in 2006 for routine use in females aged 11-12 years and catch-up vaccination to age 26 years. Administration of HPV vaccine is practice-based and typically provided in medical offices. All vaccines in use during the study period covered HPV types 16 and 18, associated with approximately 70% of cervical cancers and approximately 50% of high-grade cervical lesions. To disentangle changes associated with vaccination from other factors that could influence reported rates, we also evaluated changes in HPV vaccination coverage; rates of Papanicolaou (Pap) testing, a necessary screening test for the diagnosis of cervical intraepithelial neoplasia grade 2 or higher (CIN2+); and changes in the sexual behaviors and the rate of infection with Chlamydia trachomatis, a common sexually transmitted infection that is a marker of sexual risk. This analysis makes use of a unique data set from the state of CT (population 3.6 million) that enacted mandatory reporting of CIN grades 2, 2/3, and 3 and adenocarcinoma in situ (CIN2+) in 2008. These data add to our knowledge about the population-level impact of HPV vaccines from countries with high coverage of >70% for all 3 doses among adolescent females by showing trends in a geographic area with moderate HPV vaccine coverage of approximately 50% [14] . Furthermore, by testing whether the trends in CIN2+ vary by individual years of age and by birth cohorts and by examining different possible explanations for trends (likelihood of detection, underlying risk), we may better understand the potential role of HPV vaccine impact on cervical lesions in the United States.
METHODS
Surveillance methods have been previously described [15, 16] . In brief, in 2008, the Centers for Disease Control and Prevention began to monitor the impact of HPV vaccination through population-based surveillance of CIN2+ conducted by the Emerging Infections Program network. To facilitate implementation in CT, the state's Department of Public Health added CIN2+ to the list of mandatory reportable diseases, effective 1 January 2008. All 34 pathology laboratories that serve CT residents are in compliance with the reporting requirement. All laboratories are regularly contacted to ensure ongoing, complete, and timely reporting, and quality assurance protocols include logic and range checks and double data entry for a subset of cases. Pathology laboratories that report >80% of cases are routinely audited for completeness. This work has been deemed public health surveillance by university, state, and federal institutional review boards and thus exempt from the need for human subjects approval. Population denominators estimated for each year were obtained from the US Census Bureau American Community Survey. We restricted these analyses to women diagnosed at ages 21-39 years. Age 21 years was used for the lower limit because of changes to screening guidelines during the surveillance period that no longer recommend cervical cancer screening prior to that age.
We examined changes in rates of CIN2+ by single year of age because each subsequent cohort of women will have had a greater opportunity to be vaccinated at younger ages and prior to natural infections, thus producing declines in the rate of CIN2+ in consecutive years. To test whether the year in which declines might begin could vary by age, we fit change-point models to estimate both the timing of when a decline begins and the rate of decline after the change-point [17] . For these changepoint analyses, we used negative binomial regression models, where the outcome was the rate of CIN2+ for an age group (single years of age). These models were fit separately for each age group. Eight alternative regression models were fit, one for each year in which the declines could begin: an intercept-only model (no trend), and models where the rates were steady and then began declining (log) linearly in each year during the period 2009-2015. The Akaike information criterion scores were used to generate a weight for each of these alternative models (better-fitting models receive a higher weight), and the predicted values and parameter estimates were then averaged together.
Negative binomial regression models were also used to analyze changes in rates of CIN2+ by birth cohorts. We included dummy variables for the birth cohorts and controlled for age in years using a cubic spline. The exponentiated regression coefficient for the dummy variables gave the relative decline in cases among the indicated birth cohort compared with the referent birth cohort of 1979. Women in this birth cohort were 27 years old in 2006 when vaccines were first available in the United States and are not likely to have experienced declines attributable to vaccination because they were not in the recommended age group postlicensure.
To explore possible factors that could explain changes in CIN2+, we gathered data from other sources for ecological comparisons. First, we considered HPV vaccination coverage from 2 sources. State-specific estimates of coverage were available for adolescents aged 13-17 years from the National Immunization Survey-Teen, a population-based telephone survey that verifies vaccination histories with review of medical provider records (https://www.cdc.gov/vaccines/imz-managers/nis/about.html). National estimates of coverage for women aged 19-26 years were available from the National Health Interview Survey, a national household in-person survey of the noninstitutionalized US civilian population (https://www.cdc.gov/nchs/nhis/). Both of these sources were used to cover the full age range for which HPV vaccination has been recommended. Second, because CIN2+ is only detected after an abnormal cervical cancer screening test such as a Pap test, trends in CIN2+ may also be influenced by recent changes to guidelines that now recommend less frequent screening (every 3 years instead of annually). Therefore, we estimated the percentage of CT women who reported a Pap test in the past year from data available through the Behavioral Risk Factor Surveillance System (BRFSS; https://www.cdc.gov/brfss/). BRFSS is a federally funded, population-based national survey that collects state-level data about a variety of health status indicators. Data were analyzed for the following age groups to correspond to rates we estimated for CIN2+: 21-24, 25-29, 30-34, and 35-39 years during 2008-2014 (the last year for which these data are currently available). Finally, we considered changes in sexual behaviors, a risk factor for acquiring HPV. State-level data on sexual behaviors are readily available from the Youth Risk Behavior Surveillance System, a school-based survey of representative samples of students in grades 9-12 (https://www.cdc. gov/healthyyouth/data/yrbs/). We included measures of ever having had sexual intercourse, having had sex with ≥4 persons, and not using a condom at last sexual intercourse. We also collected data about C. trachomatis diagnoses that share epidemiologic features with HPV (eg, sexually transmitted, common, and disproportionately affecting young women) because these estimates are readily available for comparable age groups including young adult women. Chlamydia trachomatis is a reportable infection, and the number of cases among women in CT by year and age were obtained from CT Department of Public Health. Data were available for the following standard age groups: 20-24, 25-29, 30-34, and 35-39 years. Annual counts were available for 2008 through 2015 and rates estimated by dividing the number of cases by the estimated annual population size obtained from the US Census Bureau American Community Survey. For all measures, we calculated the average annual percentage change during the study period years for which data were available.
RESULTS
A total of 15 218 cases of CIN2+ were reported during 2008-2015 among residents of CT aged 21-39 years ( Table 1 ). The total number of cases reported during this surveillance period declined from 2163 in 2008 to 1540 in 2015.
Significant declines in CIN2+ after 2008 were observed among women between the ages of 21 and 26 years, whereas no significant declines were observed among women aged ≥27 years (Figure 1A and 1B; Supplementary Table 1 ). The timing of when declines began varied by single year of age, with the earliest significant decline beginning among 21-year-olds in 2010 and declines among women aged 22-26 years in 2011 and 2012. Comparing estimated rates in 2015 with the period prior to the change-point in each age group, we observed statistically significant declines of 74% (95% confidence interval [CI], 67%-79%) among women aged 21 years, 73% (95% CI, 51%-85%) among women aged 22 years, 62% (95% CI, 51%-70%) among women aged 23 years, 50% (95% CI, 28%-65%) among women aged 24 years, 34% (95% CI, 0%-56%) among women aged 25 years, and 30% (95% CI, 13%-46%) among women aged 26 years. Compared to the 1979 birth cohort, the first birth cohort to see a significant decline was born in 1985 (22% [95% CI, 4%-36%]) (Figure 2 ). Increasingly larger declines were also observed in subsequent birth cohorts through 1994 (82% [95% CI, 74%-88%]), the last birth cohort for which data were available during the study period.
Ecological comparisons are presented in Table 2 . Among women aged 21-24 years, rates of CIN2+ declined by 14.8% per year, concomitant with a 1.6% per year decrease in Pap screening and <1% annual change in reported C. trachomatis rates. Sexual risk behaviors including ever having had sex and having had sex with ≥4 people decreased among adolescents in CT during this time period (declines of 3.1% and 7.4% per year). HPV vaccination coverage with at least 1 dose increased 6.7% per year among adolescents aged [13] [14] [15] [16] [17] 
DISCUSSION
We found that rates of precancerous high-grade cervical lesions declined significantly and substantially among women aged 21-26 years in CT during 2008-2015, with the earliest and largest declines occurring among younger women. Birth cohorts that experienced significant declines began in 1985 and continued with larger declines through 1994. These results build on a small but growing body of research in the United States on trends in CIN2+ [18, 19] by using more robust analytic approaches of examining individual years of age and changepoint regression models, and by considering other possible factors that could be contributing to trends in CIN2+.
In places like the United States where data linkage studies with immunization registries are not generally possible, interpretation of these trends requires consideration of other possible explanations in addition to HPV vaccine impact. One possible explanation for declines in high-grade cervical lesions is that changes in screening guidelines for cervical cancer now recommend less frequent screening among women included in our analysis [13] . The extent to which these guidelines, first recommended in 2009 and adopted more widely by 2012, have been implemented in practice is likely to vary and has not yet been fully described. Using population-based survey data (BRFSS), we noted only a 1.6% annual decline in screening among women aged 21-24 in CT during 2008-2014, during which time CIN2+ declined in this age group by 14.8% per year. Additionally, the patterns of sequential declines by age and birth cohort suggest that the declines are not principally driven by changes in screening, which might be expected to affect all age groups similarly. Thus, it is not likely that changes in screening can fully explain the decline in CIN2+. The relatively small decline in screening in this age group could reflect the new guidelines to begin screening at age 21 years; thus, all women in this age group should have a Pap smear. We are not aware of other published estimates of changes in screening by comparable age groups (eg, 21-24 years, 25-29 years, or even individual year of age). Such data would be very useful to interpreting trends in precancerous cervical lesions. Furthermore, we note that our observations are consistent with data from other countries, including Australia and Denmark, that experienced comparable declines in high-grade cervical lesions after HPV vaccine introduction in the absence of similar changes to screening recommendations during the same period [20] [21] [22] .
Changes in sexual risk behaviors are also not likely to explain the declines we observed in CIN2+. Rates of C. trachomatis among women aged 20-24 years in CT remained steady during 2008-2015 while rates of CIN2+ were declining significantly and substantially. Though reported rates of C. trachomatis may be influenced not only by sexual risk behaviors but also by changes in diagnostic, screening, and reporting practices [23] , and screening practices may vary by age, these data do not provide compelling evidence of substantial reductions in the likelihood of acquiring HPV during the study period. We also examined sexual behaviors among high school students that revealed declines in risk, but not of a comparable magnitude to changes in rates of CIN2+. These data are somewhat limited for comparison due to the different age groups.
During the study period, declines in rates of CIN2+ among young women were accompanied by substantial increases in HPV vaccination coverage, among both adolescent and young adult females. Furthermore, the pattern and timing of the declines we observed are consistent with HPV vaccine impact as evidenced by the changes observed for individual years of age and birth cohorts. Each year, as more women who had the opportunity to be vaccinated as young adolescents (prior to sexual exposure to HPV) age into the high-risk group for cervical lesions, we expect progressive declines in the rate of disease by individual year. This is consistent with our results. Previous studies that examined trends in high-grade cervical lesions did not report data by individual years of age or birth cohorts but rather broader age categories (eg, 21-29 years) that likely confound the effects of vaccine impact and changes to cervical cancer screening guidelines [16, 24] .
Our findings should be interpreted in light of certain considerations. First, this is an ecological analysis that does not include vaccination histories for cases. Other study designs such as vaccine effectiveness studies that compare vaccination histories at the individual level between women with and without HPV-related outcomes are also important approaches and should be conducted when possible. However, an important strength of our design is that it measures population-level impact and can assess both direct and indirect effects of vaccination, thereby capturing any possible effect of herd immunity. Second, the extent to which these findings that are specific to CT may apply to other regions of the United States is not known. Finally, some of our ecological measures are not directly comparable due to limitations in available data sources such as different age groups, years, and/or regions.
Our results add to the small but growing body of literature about trends in CIN2+, an important clinical outcome, since introduction of HPV vaccines. Though it is encouraging that declines in CT have been achieved with only moderate vaccine coverage, these results should promote renewed efforts to increase vaccination coverage to achieve the vaccines full prevention potential.
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